Altamira Therapeutics .(CYTO) - 2023 Q2 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36582 Altamira Therapeutics Ltd. (Exact name of registrant as specified in its charter) Clarendon House, 2 Church Street Hamilton HM 11, Bermuda (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or F ...